This is to inform you that Curateq Biologics Private Limited, a wholly owned subsidiary of the Company secures Health Canada NOC for Bevqolva Bevacizumab Biosimilar.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Aurobindo Pharma's wholly-owned subsidiary CuraTeQ Biologics has received Notice of Compliance (NOC) from Health Canada for Bevqolva™, a bevacizumab biosimilar. This grants formal marketing authorization confirming the biosimilar meets regulatory standards for safety, efficacy, and quality comparable to the originator drug Avastin (Roche/Genentech). Bevacizumab is a monoclonal antibody used to treat cancers including colorectal and lung cancer. The product is already approved in the UK and launched commercially in 2025. Additional biosimilar applications are under review by Health Canada, and European regulatory review is ongoing with CHMP.
Positive signal for Aurobindo's biologics expansion strategy. Regulatory approvals in major markets like Canada and UK validate the biosimilar pipeline and open revenue opportunities, though no specific financial impact was disclosed.